This is a no-brainer of a short. Nexavar has a superior profile...

This is a no-brainer of a short. Nexavar has a superior profile to PI-88, and Onyx is streaking ahead in clinical trials thanks to unheard-of efficacy of their wonder drug. We will soon see PGL trade close to cash value, with PI-88 effectively worthless.

They have just been "scooped." Price target $1.50. Broker report must be a last-ditch effort to dump shares on unsuspecting punters. Give this one a wide berth - she's going down with a gurgle.